CRDL
Cardiol Therapeutics Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.99 | $1.28 | -36% |
| Two Sigma Investments re-entered | Q4 2024(8Q snapshot) | 6Q | $1.86 | $1.28 | -31% |
| Renaissance Technologies | Q2 2026(8Q snapshot) | 1Q | $1.37 | $1.28 | -7% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Fundamentals
XBRL · Cardiol Therapeutics Inc.Not enough XBRL history to plot. Cardiol Therapeutics Inc.hasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Cardiol Therapeutics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KFORM 6-KMay 26, 2026
- 6-KFORM 6-KMay 14, 2026
- 6-KFORM 6-KMay 11, 2026
- 6-KFORM 6-KMay 7, 2026
- 6-KFORM 6-KApr 28, 2026
- 6-KFORM 6-KApr 14, 2026
- 6-KFORM 6-KApr 10, 2026
- 6-KFORM 6-KApr 1, 2026
- 6-KFORM 6-KFeb 25, 2026
- 6-KFORM 6-KFeb 10, 2026
- 6-KFORM 6-KFeb 2, 2026
- 6-KFORM 6-KJan 26, 2026
- 6-KFORM 6-KJan 23, 2026
- 6-KFORM 6-KJan 16, 2026
- 6-KFORM 6-KJan 13, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $1.32 | $1.28 | -3% |
| Renaissance Technologies | Q2 2026 | open | $1.37 | $1.28 | -7% |
| Citadel Advisors | Q4 2025 | Q1 2026 | $1.02 | $1.04 | +2% |
| Two Sigma Investments | Q4 2025 | open | $1.02 | $1.28 | +25% |
| Two Sigma Investments | Q4 2024 | Q1 2025 | $1.86 | $1.22 | -34% |
| Citadel Advisors | Q3 2024 | Q2 2025 | $1.99 | $1.14 | -43% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.